AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors

Reuters

Feb 19

AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors

AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The company said Europe accounts for about 28% of global irreversible electroporation $(IRE)$ procedures, with annual IRE procedures estimated to have surpassed 45,000 globally. AngioDynamics also plans to initiate the LIVER-IRE Global Registry with the University of Manchester to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602190830BIZWIRE_USPR_____20260219_BW441352) on February 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612007914"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612007914\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612007914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612007914","market":"nz","top_or_hot":-1,"title":"AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The company said Europe accounts for about 28% of global irreversible electroporation <a href=\"https://laohu8.com/S/IRE\">$(IRE)$</a> procedures, with annual IRE procedures estimated to have surpassed 45,000 globally. AngioDynamics also plans to initiate the LIVER-IRE Global Registry with the University of Manchester to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602190830BIZWIRE_USPR_____20260219_BW441352) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-19 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The company said Europe accounts for about 28% of global irreversible electroporation <a href=\"https://laohu8.com/S/IRE\">$(IRE)$</a> procedures, with annual IRE procedures estimated to have surpassed 45,000 globally. AngioDynamics also plans to initiate the LIVER-IRE Global Registry with the University of Manchester to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602190830BIZWIRE_USPR_____20260219_BW441352) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLbsKXwJ:1","article_id":"2612007914","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612007914","pubTimestamp":1771507914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The company said Europe accounts for about 28% of global irreversible electroporation  procedures, with annual IRE procedures estimated to have surpassed 45,000 globally. AngioDynamics also plans to initiate the LIVER-IRE Global Registry with the University of Manchester to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"AngioDynamics在欧洲扩大了纳米刀在肝脏、胰腺、肾脏和前列腺肿瘤的适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":0.9},"content_text":"AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors\n    \n\n        AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The company said Europe accounts for about 28% of global irreversible electroporation $(IRE)$ procedures, with annual IRE procedures estimated to have surpassed 45,000 globally. AngioDynamics also plans to initiate the LIVER-IRE Global Registry with the University of Manchester to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602190830BIZWIRE_USPR_____20260219_BW441352) on February 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}